PDCD1 and neoplasm: Therapeutic intervention of the pathway using EAGLE-301, a Herceptin-sialidase antibody-enzyme conjugate let to targeted desialylation of the tumor microenvironment and resulted in intratumoral T cell activation and T cell- dependent tumor rejection, which was non-redundant to PD-1 or CTLA-4 inhibition.